Media

The partnership will enable Evonik to provide commercial quantities of collagen for applications in skincare such as anti-aging and hydrating creams.

Interface Polymers’ Polarfin® additives simplify the processing and recycling of plastics such as mixtures of polyethylene and polypropylene.

The Chinese company is a technological leader in graphene materials that improve the range, robustness, charging speed, and service life of lithium-ion batteries.

Allay Therapeutics has developed an implant for treating pain after knee surgery. It is inserted directly into the knee and may relieve pain for up to three weeks

Evonik Venture Capital has invested in Fund VIII of Global Brain Corporation, a Japanese venture capital company. The move marks Evonik’s first investment in the country.

Evonik Venture Capital has invested in two sustainability funds: Azolla Ventures I and the Chrysalix Venture Capital’s Carbon Neutrality Fund.

Vivasure Medical announced the closing of the first tranche of €22 million ($23M) as part of its Series D financing round that could reach up to €52 million ($54M) in total.

Evonik invested in Citrine Informatics, provider of the Citrine Platform, a leading AI and smart data management software platform for materials and chemicals development.

3D printed tablets with better drug delivery improve patients’ health.

Dutch AgTech scale-up closes 34M fund raise to accelerate its international growth and scale up plans. The funding is provided by impact investor ECBF and ABN AMRO and includes existing shareholders Evonik and VisVires New Protein.

Biograil ApS, a Copenhagen based biotech company developing a unique oral device for delivery of biologics, announced the closing of a Seed 2 funding of 3.2 million Euro. Evonik Venture Capital participated as a new investor.

Evonik Venture Capital has invested in CircumFix Solutions, a U.S.-based start-up that has developed a new sternal closure device to improve patient recovery after open chest surgery.

Evonik has invested in start-up Revivo BioSystems to support the development of a realistic 4D model of human skin that provides an alternative to animal testing.

Evonik is extending its corporate venture capital activities in China with investments into GRC SinoGreen Fund V and Richland VC Fund III.

Evonik has acquired German biotech company JeNaCell. The acquisition expands Evonik’s biomaterials portfolio to provide biotechnologically derived cellulose.

Evonik’s venture capital arm has invested in chembid, the world’s largest search engine and market intelligence platform for chemicals, to strengthen the company’s e-commerce activities.

Evonik has acquired a minority stake in Chinese company UnionTech through its Venture Capital unit.

Evonik has made a second investment in HPNow, based in Copenhagen, Denmark, through its venture capital unit.